{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:37:37Z","timestamp":1790030257277,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ebiom.2021.103651","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T23:48:46Z","timestamp":1636588126000},"page":"103651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis"],"prefix":"10.1016","volume":"73","author":[{"given":"Brian M.","family":"Maas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Lommerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Plock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha A.","family":"Railkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y. Amy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Guiastrennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Spellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Roadcap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Kalinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juin","family":"Fok-Seang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Catchpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Espeseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpit A.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios O.","family":"Aliprantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2021.103651_bib0001","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103651_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30282-6","article-title":"Recent successes in therapeutics for Ebola virus disease: no time for complacency","volume":"20","author":"Iversen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2021.103651_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/571609","article-title":"Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: A real-world perspective","volume":"2014","author":"Homaira","year":"2014","journal-title":"Int J Pediatr"},{"key":"10.1016\/j.ebiom.2021.103651_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jtbi.2019.01.017","article-title":"Dose finding for new vaccines: The role for immunostimulation\/immunodynamic modelling","volume":"465","author":"Rhodes","year":"2019","journal-title":"J Theor Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103651_bib0005","first-page":"93","article-title":"Good practices in model-informed drug discovery and development: practice, application, and documentation","volume":"5","author":"Marshall","year":"2016","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103651_bib0006","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose Nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103651_bib0007","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O'Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2021.103651_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103651_bib0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103651_bib0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1442-200X.2006.02179.x","article-title":"Guidelines for the use of palivizumab in infants and young children with congenital heart disease","volume":"48","author":"Nakazawa","year":"2006","journal-title":"Pediatr Int: Off J Jpn Pediatr Soc"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103651_bib0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jpids\/piz011","article-title":"Respiratory Syncytial Virus\u2013Associated Outpatient Visits Among Children Younger Than 24 Months","volume":"8","author":"Lively","year":"2019","journal-title":"J Pediat Infect Dis Soc"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103651_bib0012","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103651_bib0013","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cpdd.883","article-title":"A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults","volume":"10","author":"Aliprantis","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"33","key":"10.1016\/j.ebiom.2021.103651_bib0014","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2021.103651_bib0015","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","author":"Sim\u00f5es","year":"2020","journal-title":"Clin Infect Dis An Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ebiom.2021.103651_bib0016","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103651_bib0017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/INF.0000000000000257","article-title":"Respiratory syncytial virus surveillance in the United States, 2007\u20132012: results from a national surveillance system","volume":"33","author":"McGuiness","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"388","key":"10.1016\/j.ebiom.2021.103651_bib0018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103651_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence of fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103651_bib0020","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.ejcn.1602667","article-title":"Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart","volume":"61","author":"Fenton","year":"2007","journal-title":"Eur J Clin Nutr"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103651_bib0021","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose Respiratory Syncytial Virus prefusion F-targeting monoclonal antibody administered as a single Dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103651_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the Respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.ebiom.2021.103651_bib0023","first-page":"1092","article-title":"V2ACHER: Visualization of complex trial data in pharmacometric analysis with covariates","volume":"10","author":"Lommerse","year":"2021","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.ebiom.2021.103651_bib0024","unstructured":"Lommerse J., Green M., Espeseth A., Vora K.A., Aliprantis A., Finelli L., (Found in) Translation\u2013Cotton rat modelling and validation with model based meta-analysis (MBMA) for RSV. ACoP11, 2020."},{"key":"10.1016\/j.ebiom.2021.103651_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-017-0019-3","article-title":"An Z. Antibody therapies for the prevention and treatment of viral infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103651_bib0026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ebiom.2021.103651_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618770518","article-title":"Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus","volume":"26","author":"Boukhvalova","year":"2018","journal-title":"Antivir Chem Chemother"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103651_bib0028","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/vim.2017.0147","article-title":"Establishing correlates of protection for vaccine development: Considerations for the respiratory syncytial virus vaccine field","volume":"31","author":"Kulkarni","year":"2018","journal-title":"Viral Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103651_bib0029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13543784.2020.1735349","article-title":"Emerging small and large molecule therapeutics for respiratory syncytial virus","volume":"29","author":"Bergeron","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103651_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175792","article-title":"Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV\/A and RSV\/B","volume":"12","author":"Hause","year":"2017","journal-title":"PloS One"},{"issue":"45","key":"10.1016\/j.ebiom.2021.103651_bib0031","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1016\/j.vaccine.2018.09.056","article-title":"Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset","volume":"36","author":"Mas","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103651_bib0032","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/irv.12727","article-title":"Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017","volume":"14","author":"Liu","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.ebiom.2021.103651_bib0033","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-021-26117-x","article-title":"SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques","volume":"12","author":"Roozendaal","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2021.103651_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642100445X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642100445X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:11:31Z","timestamp":1762456291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642100445X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"alternative-id":["S235239642100445X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103651","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Merck Sharp & Dohme Corp. and The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103651"}}